Robert A. Freedman
Leveraging decades of experience, Rob provides a wide range of corporate and securities legal services to innovative late-stage and public companies in the life sciences and technology industries. He represents issuers and underwriters in going public transactions, including IPOs, de-SPACs, reverse mergers and direct listings, and in follow-on offerings and private placements of equity and debt securities. Rob previously co-chaired Fenwick’s Public Company and Capital Markets practice.
[Rob] has the ability to find a solution in any difficult situation and he offers great guidance."
- Aeglea BioTherapeutics
- Aceragen
- AnaptysBio
- Audentes Therapeutics
- Augmedix
- BioAge Labs
- Castlight Health
- Day One Biopharmaceuticals
- Dermira
- DICE Therapeutics
- Elevation Oncology
- Graybug Vision
- KalVista
- Loxo Oncology
- Morphic Holding
- Neoleukin Therapeutics
- Nurix Therapeutics
- Obalon Therapeutics
- Passage Bio
- Prelude Therapeutics
- Sema4
- Sierra Oncology
- Silver Spring Networks
- Stoke Therapeutics
- Sutro Biopharma
- Third Harmonic Bio
- Upwork
- Loxo Oncology in its $8B acquisition by Lilly
- Aceragen in its merger with Idera Pharmaceuticals
- Alpine Immune Sciences in its $4.9B acquisition by Vertex Pharmaceuticals
- Augmedix in its private placement and reverse merger with Malo Holdings Corp.
- Castlight Health in its $370M acquisition by Vera Whole Health
- DICE Therapeutics in its $2.4B acquisition by Eli Lilly
- Graybug Vision in its merger with CalciMedica
- KalVista Pharmaceuticals in its merger with Carbylan Therapeutics
- Morphic Holdings, Inc. in its $3.2B acquisition by Eli Lilly and Company
- Neoleukin Therapeutics in its reverse merger with Neurogene
- OncoGenex Pharmaceuticals in its merger with Achieve Life Science
- Sema4 in its combination agreement with CM Life Sciences SPAC
- Data Domain in its $2.4B acquisition by EMC
- Cisco Systems in its $3.2B acquisition of WebEx Communications
- Macromedia in its $3.4B merger with Adobe
- Zappos.com in its $847M acquisition by Amazon.com
- Day One in its pending $285M acquisition of Mersana Therapeutics
- Chambers USA recognized Rob as a leading lawyer in capital markets in California (2022)
- Chambers USA ranked Rob as a top capital markets lawyer nationwide (2019 – 2022)
- US News recognized Rob for his excellence in securities and capital markets law and corporate law (2019)
- The Legal 500 recognized Rob for his capital markets practice (2016 – 2020)
Recognition
- Image
Chambers Global and Chambers USA2020 - 2025Chambers USA ranked Rob as a top lawyer in Capital Markets: Debt & Equity in California and the Western United States.
- Image
U.S. News - Best Lawyers2019-2021Named Rob "Lawyer of the Year" in corporate law (2020), and recognized him among “The Best Lawyers in America” for his work in corporate law, and securities and capital markets law (2019 – 2021).
- Image
The Legal 5002022-2023Highlighted among the United States’ leading lawyers for capital markets and healthcare: life sciences work.